Celgene (NASDAQ:CELG) issued an update on its FY 2019 earnings guidance on Thursday morning. The company provided earnings per share guidance of $10.60-10.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.42. The company issued revenue guidance of $17-17.2 billion, compared to the consensus revenue estimate of $17 billion.Celgene also updated its FY19 guidance to $10.60-10.80 EPS.
CELG stock traded up $0.40 on Thursday, reaching $88.46. 8,883,593 shares of the company were exchanged, compared to its average volume of 15,252,307. Celgene has a 12 month low of $58.59 and a 12 month high of $102.54. The firm has a market capitalization of $61.43 billion, a P/E ratio of 12.93, a price-to-earnings-growth ratio of 0.46 and a beta of 1.44. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 4.06.
A number of equities research analysts have weighed in on CELG shares. Morgan Stanley decreased their price target on shares of Celgene from $93.00 to $88.00 and set an equal weight rating on the stock in a research note on Wednesday, December 19th. Leerink Swann set a $112.00 price target on shares of Celgene and gave the stock a hold rating in a research note on Friday, October 26th. BidaskClub upgraded shares of Celgene from a strong sell rating to a sell rating in a research note on Friday, January 4th. Zacks Investment Research upgraded shares of Celgene from a hold rating to a strong-buy rating and set a $99.00 price target on the stock in a research note on Wednesday, January 23rd. Finally, ValuEngine upgraded shares of Celgene from a strong sell rating to a sell rating in a research note on Friday, January 4th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $110.00.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/4116191/celgene-celg-updates-fy-2019-earnings-guidance.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: What is a back-end load?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.